Status:
UNKNOWN
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Breast Cancer
Tumor Angiogenesis
Eligibility:
FEMALE
18+ years
Brief Summary
Technetium-99m NC100692 Injection is under development as a diagnostic radiopharmaceutical for targeting angiogenesis associated with diseases such as primary and metastatic cancer, and for targeting ...
Detailed Description
Angiogenesis is the formation of new blood vessels from the existing vascular bed. Certain integrins are upregulated while angiogenesis and myocardial fibrogenesis. Therefore, targeting an integrin wi...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Patients with unknown breast cancer but unclear lesions in the breast on other modalities or patients at high risk for breast cancer (BRCA, familial)- Arm 1
- patients with breast cancer referred for 18-FDG PET-CT for staging or re-staging- Arm 2
- Study cohort will include 15 patients with locally advanced breast cancer. Patients will undergo imaging prior to treatment and at its end- Arm 3
- Written signed informed consent to participate in the study.
- Patients not pregnant or lactating.
Exclusion
- Patients with breast cancer who do not fall into one of the three study arms.
- Pregnant or lactating females.
- Participation in another investigational study.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01503697
Start Date
January 1 2012
Last Update
January 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine,Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239